Brief: Glenmark Pharma Receives FDA Approval To Expand Ryaltris Use For Children Aged 6 To Under 12
21/07/2026 05:37
BRIEF-Glenmark Pharma Receives FDA Approval To Expand Ryaltris Use For Children Aged 6 To Under 12 July 21 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS:
GLENMARK PHARMA - RECEIVES FDA APPROVAL TO EXPAND RYALTRIS USE FOR CHILDREN AGED 6 TO UNDER 12
GLENMARK PHARMA - RYALTRIS NOW APPROVED IN U.S. FOR ADULTS AND CHILDREN AGED 6 YEARS AND OLDER
Source text: ID:nNSE8LMtD9
Further company coverage: GLEN.NS
((reuters.briefs@thomsonreuters.com;))
Recent news on Glenmark Pharmaceuticals
See all newsBrief: Glenmark Pharma Says Unit Launches Ryaltris Nasal Spray In Brazil For Allergic Rhinitis
Brief: Glenmark Pharma US Unit Launches Calcium Gluconate Injection USP In Multiple Vial Sizes
India's Glenmark Pharma gains most in three weeks on US approval for Flonase nasal spray
Brief: Glenmark Pharma Gets U.S. FDA Approval For Fluticasone Propionate Nasal Spray 0.05 Mg/Spray
India's Glenmark Pharmaceuticals falls as brokerage flags softer-than-expected quarter